PlainRecalls
FDA Drug Moderate Class II Completed

Zonisamide Capsules, USP, 100 mg, packaged in: a) 100-count bottle (NDC 68462-130-01); b) 500-count bottle (NDC 68462-130-05), Rx only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430

Reported: May 4, 2022 Initiated: April 25, 2022 #D-0793-2022

Product Description

Zonisamide Capsules, USP, 100 mg, packaged in: a) 100-count bottle (NDC 68462-130-01); b) 500-count bottle (NDC 68462-130-05), Rx only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430

Reason for Recall

cGMP deviations

Details

Units Affected
a) 7,044 bottles; b) 1,014 bottles
Distribution
USA nationwide
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Zonisamide Capsules, USP, 100 mg, packaged in: a) 100-count bottle (NDC 68462-130-01); b) 500-count bottle (NDC 68462-130-05), Rx only, Manufactured by: Glenmark Pharmaceuticals, Inc., USA Monroe, NC 28110, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: a) 7,044 bottles; b) 1,014 bottles.
Why was this product recalled?
cGMP deviations
Which agency issued this recall?
This recall was issued by the FDA Drug on May 4, 2022. Severity: Moderate. Recall number: D-0793-2022.